US Patent 6872700 Methods for glucagon suppression
Patent 6872700 was granted and assigned to Amylin Pharmaceuticals on March, 2005 by the United States Patent and Trademark Office.
All edits
Edits on 2 Oct, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 14 Aug, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 24 Jul, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
0
Edits on 1 Feb, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 13 Dec, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 19 Oct, 2023
Golden AI
Edits made to:
Infobox (+11 properties)
Article (+464 characters)
Article
Patent abstract
Methods for use of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, for lowering glucagon levels and/or suppressing glucagon secretion in a subject are provide. These methods are useful in treating hyperglucagonemia and other conditions that would be benefited by lowering plasma glucagon or suppressing glucagon secretion.
Infobox
Is a
Patent Applicant
0
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Andrew A. Young0
Bronislava Gedulin0
Date of Patent
March 29, 2005
0Patent Application Number
098893310
Date Filed
January 14, 2000
0Patent Primary Examiner
Golden AI
Edits made to:
US Patent 6872700 Methods for glucagon suppression
Find more entities like US Patent 6872700 Methods for glucagon suppression
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.